Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73351
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73351
Character Range: 17246–17908

73351              A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non‑small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.                                                                                                                                 397.35